Emerging Pharmacological Approaches for Psychosis and Agitation in Alzheimer's Disease.

ABSTRACT: Psychosis and agitation are among the most distressing neuropsychiatric symptoms (NPSs) of Alzheimer's disease (AD), linked to faster disease progression and earlier admission to nursing homes. While nonpharmacological treatments may alleviate mild behavioral symptoms, more severe syndromes often require pharmacological intervention. Brexpiprazole is the only medication approved for agitation in AD, although its limited clinical efficacy has raised criticism. No drugs have been approved for treating psychosis in AD, highlighting the critical need for new, effective, and safe treatments. Recent studies have elucidated part of the neurobiological basis of NPSs in the AD brain, offering insights for testing repurposed and novel drugs. We conducted a comprehensive nonsystematic literature revi

SUBMITTER: Imbimbo C 

PROVIDER: S-EPMC11769872 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature